Book contents
- Treatment-Related StrokeIncluding Iatrogenic and In-hospital Strokes
- Treatment-Related Stroke
- Copyright page
- Dedication
- Contents
- Contributors
- Preface
- Section I Iatrogenic ischemic strokes: peri- and postoperative strokes
- Section II Iatrogenic ischemic strokes: stroke after endovascular procedures
- Section III Iatrogenic ischemic strokes: other causes
- Section IV Iatrogenic hemorrhagic strokes: thrombolysis-related hemorrhagic strokes
- Section V Iatrogenic hemorrhagic strokes: intracranial bleeding
- Section VI Iatrogenic hemorrhagic strokes: anticoagulation-related intracranial hemorrhage
- Section VII Other uncommon causes of iatrogenic stroke
- Section VIII Cerebral venous thrombosis
- Section IX Medication reversal and restarting in patients with iatrogenic strokes
- Index
- References
Section VII - Other uncommon causes of iatrogenic stroke
Published online by Cambridge University Press: 20 October 2016
Book contents
- Treatment-Related StrokeIncluding Iatrogenic and In-hospital Strokes
- Treatment-Related Stroke
- Copyright page
- Dedication
- Contents
- Contributors
- Preface
- Section I Iatrogenic ischemic strokes: peri- and postoperative strokes
- Section II Iatrogenic ischemic strokes: stroke after endovascular procedures
- Section III Iatrogenic ischemic strokes: other causes
- Section IV Iatrogenic hemorrhagic strokes: thrombolysis-related hemorrhagic strokes
- Section V Iatrogenic hemorrhagic strokes: intracranial bleeding
- Section VI Iatrogenic hemorrhagic strokes: anticoagulation-related intracranial hemorrhage
- Section VII Other uncommon causes of iatrogenic stroke
- Section VIII Cerebral venous thrombosis
- Section IX Medication reversal and restarting in patients with iatrogenic strokes
- Index
- References
- Type
- Chapter
- Information
- Treatment-Related StrokeIncluding Iatrogenic and In-Hospital Strokes, pp. 203 - 240Publisher: Cambridge University PressPrint publication year: 2016
References
References
George, M G, Tong, X, Kuklina, E V, Labarthe, D R. Trends in stroke hospitalizations and associated risk factors among children and young adults, 1995–2008. Ann Neurol. 2011; 70:713–21.Google Scholar
Dias, M, Sekhar, L. Intracranial hemorrhage from aneurysms and arteriovenous malformations during pregnancy and the puerperium. Neurosurgery. 1990; 27:855–65.Google Scholar
James, A, Bushnell, C D, Jaminson, M G, Myers, E R. Incidence and risk factors for stroke in pregnancy and puerperium. Obstet Gynecol. 2005; 106:509–16.CrossRefGoogle Scholar
Say, L, Souza, J P, Pattinson, R C; WHO working group on Maternal Mortality and Morbidity classifications. Maternal near miss: Towards a standard tool for monitoring quality of maternal health care. Best Pract Res Clin Obstet Gynaecol. 2009; 23:287–96.CrossRefGoogle ScholarPubMed
Kuklina, E V, Tong, X, Bansil, P, George, M G, Callaghan, W M. Trends in pregnancy hospitalizations that included a stroke in the United States from 1994 to 2007: Reasons for concern? Stroke. 2011; 42:2564–70.CrossRefGoogle ScholarPubMed
Sharshar, T, Lamy, C, Mas, J L, The Stroke in Pregnancy Group. Incidence and causes of stroke associated with pregnancy and puerperium: a study in public hospitals of Ile de France. Stroke. 1995; 26:930–6.CrossRefGoogle ScholarPubMed
Liang, C C, Chang, S D, Lai, S L, et al. Stroke complicating pregnancy and the puerperium. Eur J Neurol. 2006; 13:1256–60.Google Scholar
Wiebers, D O, Whisnant, J P. The incidence of stroke among pregnant women in Rochester, Minn, 1955 through 1979. JAMA. 1985; 254:3055–7.Google Scholar
Awada, A, al Rajeh, S, Duarte, R, Russell, N. Stroke and pregnancy. Int J Gynaecol Obstet. 1995; 48:157–61.Google Scholar
Kittner, S J, Stern, B J, Feeser, B R, et al. Pregnancy and the risk of stroke. N Engl J Med. 1996; 335:768–74.Google Scholar
Witlin, A G, Friedman, S A, Egerman, R S, Frangieh, A Y, Sibai, B M. Cerebrovascular disorders complicating pregnancy: beyond eclampsia. Am J Obstet Gynecol. 1997; 176:1139–45.Google Scholar
Skidmore, F M, Williams, L S, Fradkin, K D, Alonso, R J, Biller, J. Presentation, etiology and outcome of stroke in pregnancy and puerperium. J Stroke Cerebrovasc Dis. 2001; 10:1–10.CrossRefGoogle ScholarPubMed
Jeng, J S, Tang, S C, Yip, P K. Incidence and etiologies of stroke during pregnancy and puerperium as evidenced in Taiwanese women. Cerebrovasc Dis. 2004; 18:290–5.CrossRefGoogle ScholarPubMed
Ros, H S, Lichtestein, P, Bellocco, R, Petersson, R, Cnattingius, S. Increased risks of circulatory diseases in late pregnancy and puerperium. Epidemiology. 2001; 12:456–60.Google Scholar
Hunter, S, Robson, S C. Adaptation of the maternal heart in pregnancy. Brit Heart J. 1992; 68:540–3.Google Scholar
Bremme, K A. Haemostatic changes in pregnancy. Best Pract Res Clin Haematol. 2003; 16:153–68.CrossRefGoogle ScholarPubMed
ACOG Committee on Obstetric Practice. ACOG Committee Opinion Number 299, September 2004. Guidelines for diagnostic imaging during pregnancy. Obstet Gynecol. 2004; 104:647–51.Google Scholar
Kanal, E, Borgstede, J P, Barkovich, A J, et al. American College of Radiology. American College of Radiology White Paper on MR Safety. Am J Roentgenol. 2002; 178:1335–47.Google Scholar
Stoddard, M F, Longaker, R A, Vuocolo, L M, Dawkins, P R. Trans-esophageal echocardiography in the pregnant patient. Am Heart J. 1992; 124:785–7.Google Scholar
Lanska, D J, Kryscio, R J. Risk factors for peripartum and postpartum stroke and intracranial venous thrombosis. Stroke. 2000; 31:1274–82.Google Scholar
Ros, H S, Lichtenstein, P, Bellocco, R, Petersson, G, Cnattingius, S. Pulmonary embolism and stroke in relation to pregnancy: How can high-risk women be identified? Am J Obstet Gynecol. 2002; 186:198–203.Google Scholar
Clark, S L, Hankins, G D, Dudley, D A, Dildy, G A, Porter, T F. Amniotic fluid embolism: Analysis of the national registry. Am J Obstet Gynecol. 1995; 172:1158–69.CrossRefGoogle ScholarPubMed
Sibai, B, Dekker, G, Kupferminc, M. Pre-eclampsia. Lancet. 2005; 365:785–99.CrossRefGoogle ScholarPubMed
Moodley, J, Kalane, G. A review of the management of eclampsia: practical issues. Hypertens Pregnancy. 2006; 25:47–62.Google Scholar
Roberts, J M, Cooper, D W. Pathogenesis and genetics of pre-eclampsia. Lancet. 2001; 357:53–6.Google Scholar
Elkayam, U, Akhter, M W, Singh, H, et al. Pregnancy-associated cardiomyopathy: Clinical characteristics and a comparison between early and late presentation. Circulation. 2005; 111:2050–5.Google Scholar
Abboud, J, Murad, Y, Chen-Scarabelli, C, Saravolatz, L, Scarabelli, T. Peripartum cardiomyopathy: a comprehensive review. Int J Cardiol. 2007; 118:295–303.CrossRefGoogle ScholarPubMed
Pearson, G D, Veille, J C, Rahimtoola, S, et al. Peripartum cardiomyopathy: National Heart, Lung, and Blood Institute and Office of Rare Diseases (National Institutes of Health) workshop recommendations and review. JAMA. 2000; 283:1183–8.Google Scholar
Mas, J L, Lamy, C. Stroke in pregnancy and the puerperium. J Neurol. 1998; 245:305–13.Google Scholar
Fugate, J E, Ameriso, S F, Ortiz, G, et al. Variable presentations of postpartum angiopathy. Stroke. 2012; 43:670–6.Google Scholar
Huang, C Y, Chen, C A, Hsieh, C Y, Cheng, W F. Intracerebral hemorrhage as initial presentation of gestational choriocarcinoma: A case report and literature review. Int J Gynecol Cancer. 2007; 17:1166–71.Google Scholar
Lanska, D J, Kryscio, R J. Peripartum stroke and intracranial venous thrombosis in the National Hospital Discharge Survey. Obstet Gynecol. 1997; 89:413–18.Google Scholar
Lanska, D J, Kryscio, R J. Stroke and intracranial venous thrombosis during pregnancy and puerperium. Neurology. 1998; 51:1622–8.CrossRefGoogle ScholarPubMed
Cantu, C, Barinagarrementaria, F. Cerebral venous thrombosis associated with pregnancy and the puerperium: a review of 67 cases. Stroke. 1993; 24:1880–4.Google Scholar
Furie, K L, Kasner, S E, Adams, R J, et al. American Heart Association Stroke Council, Council on Cardiovascular Nursing, Council on Clinical Cardiology, and Interdisciplinary Council on Quality of Care and Outcomes Research. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for Healthcare Professionals from the American Heart Association/American Stroke Association. Stroke. 2011; 42:227–76.Google ScholarPubMed
Bates, S, Greer, I, Pabinger, I, Sofaer, S, Hirsch, J. Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy. Chest. 2008; 133:844S–886S.Google Scholar
Kozer, E, Nikfar, S, Costei, A, et al. Aspirin consumption during the first trimester of pregnancy and congenital anomalies: a meta-analysis. Am J Obstet Gynecol. 2002; 187:1623–30.Google Scholar
Coomarasamy, A, Honest, H, Papaioannou, S, Gee, H, Khan, K S. Aspirin for prevention of preeclampsia in women with historical risk factors: a systematic review. Obstet Gynecol. 2003; 101:1319–32.Google Scholar
Greer, I A, Nelson-Piercy, C. Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy. Blood. 2005; 106:401–7.CrossRefGoogle ScholarPubMed
Leonhardt, G, Gaul, C, Nietsch, H H, Buerke, M, Schleussner, E. Thrombolytic therapy in pregnancy. J Thromb Thrombolysis. 2006; 21:271–6.Google Scholar
Dapprich, M, Boessenecker, W. Fibrinolysis with alteplase in a pregnant woman with stroke. Cerebrovasc Dis. 2002; 13:290.Google Scholar
Elford, K, Leader, A, Wee, R, Stys, P K. Stroke in ovarian hyperstimulation syndrome in early pregnancy treated with intra-arterial rt-PA. Neurology. 2002; 59:1270–2.Google Scholar
Johnson, D M, Kramer, D C, Cohen, E, et al. Thrombolytic therapy for acute stroke in late pregnancy with intra-arterial recombinant tissue plasminogen activator. Stroke. 2005; 36:e53–e55.Google Scholar
Wiese, K M, Talkad, A, Mathews, M, Wang, D. Intravenous recombinant tissue plasminogen activator in a pregnant woman with cardioembolic stroke. Stroke. 2006; 37:2168–9.Google Scholar
Murugappan, A, Coplin, W M, Al-Sadat, A N, et al. Thrombolytic therapy of acute ischemic stroke during pregnancy. Neurology. 2006; 66:768–70.Google Scholar
Li, Y, Margraf, J, Kluck, B, Jenny, D, Castaldo, J. Thrombolytic therapy for ischemic stroke secondary to paradoxical embolism in pregnancy: A case report and literature review. Neurologist. 2012; 18:44–8.CrossRefGoogle ScholarPubMed
Mantoan Ritter, L, Schüler, A, Gangopadhyay, R, et al. Successful thrombolysis of stroke with intravenous alteplase in the third trimester of pregnancy. J Neurol. 2014; 261:632–4.CrossRefGoogle ScholarPubMed
Méndez, J C, Masjuán, J, García, N, de Leciñana, M. Successful intra-arterial thrombolysis for acute ischemic stroke in the immediate postpartum period: Case report. Cardiovasc Intervent Radiol. 2008; 31:193–5.Google Scholar
Rønning, O M, Dahl, A, Bakke, S J, Hussain, A I, Deilkås, E. Stroke in the puerperium treated with intra-arterial rt-PA. J Neurol Neurosurg Psychiatry. 2010; 81:585–6.Google Scholar
Barrett, J M, Van Hooydonk, J E, Boehm, F H. Pregnancy-related rupture of arterial aneurysms. Obstet Gynecol Surv. 1982; 37:557–66.Google Scholar
Marshman, L A, Aspoas, A R, Rai, M S, Chawda, S J. The implications of ISAT and ISUIA for the management of cerebral aneurysms during pregnancy. Neurosurg Rev. 2007; 30:177–80.Google Scholar
Meyers, P M, Halbach, V V, Malek, A M, et al. Endovascular treatment of cerebral artery aneurysms during pregnancy: Report of three cases. Am J Neuroradiol. 2000; 21:1306–11.Google Scholar
Piotin, M, Filho, C B A, Kothimbakam, R, Moret, J. Endovascular treatment of acutely ruptured intracranial aneurysm in pregnancy. Am J Obstet Gynecol. 2001; 185:1261–2.Google Scholar
Marshman, L A G, Aspoas, A R, Rai, M S. Endovascular treatment of ruptured intracranial aneurysms during pregnancy: Letter. Arch Gynecol Obstet. 2005; 272:93.CrossRefGoogle Scholar
Bateman, B, Schumacher, H, Bushnell, C D, et al. Intracerebral hemorrhage in pregnancy. Frequency, risk factors, and outcome. Neurology. 2006; 67:424–9.Google Scholar
Sawin, P. Spontaneous subarachnoid hemorrhage in pregnancy and the puerperium. In Loftus, C, ed. Neurological Aspects of Pregnancy. Park Ridge, IL: American Association of Neurological Surgeons; 1996: 85–99.Google Scholar
Roman, H, Descargues, G, Lopes, M, et al. Subarachnoid hemorrhage due to cerebral aneurysmal rupture during pregnancy. Acta Obstet Gynecol Scand. 2004; 83:330–4.Google Scholar
Wright, V C, Schieve, L A, Reynolds, M A, Jeng, G. Assisted reproductive technology surveillance in United States, 2002. MMWR. 2005; 54:1–24.Google Scholar
Whelan, J G, Vlahos, N F. The ovarian hyperstimulation syndrome. Fertil Steril. 2000; 73:893–6.CrossRefGoogle ScholarPubMed
Chan, W S, Dixon, M E. The “ART” of thromboembolism: a review of assisted reproductive technology and thromboembolic complications. Thromb Res. 2008; 121:713–26.Google Scholar
Kodama, H, Fukuda, J, Karube, H, et al. Status of the coagulation and fibrinolytic systems in ovarian hyperstimulation syndrome. Fertil Steril. 1996; 66:417–24.Google Scholar
References
Watson, T, Shantsila, E, Lip, G Y. Mechanisms of thrombogenesis in atrial fibrillation: Virchow’s triad revisited. Lancet. 2009; 373(9658):155–66.Google Scholar
Manning, W J, et al. Impaired left atrial mechanical function after cardioversion: Relation to the duration of atrial fibrillation. J Am Coll Cardiol. 1994; 23(7):1535–40.Google Scholar
O’Neill, P G, et al. Return of atrial mechanical function following electrical conversion of atrial dysrhythmias. Am Heart J. 1990; 120(2):353–9.Google Scholar
Shapiro, E P, et al. Transient atrial dysfunction after conversion of chronic atrial fibrillation to sinus rhythm. Am J Cardiol. 1988; 62(17):1202–7.Google Scholar
Ikram, H, Nixon, PG, Arcan, T. Left atrial function after electrical conversion to sinus rhythm. Br Heart J. 1968; 30(1):80–3.Google Scholar
Manning, W J, et al. Pulsed Doppler evaluation of atrial mechanical function after electrical cardioversion of atrial fibrillation. J Am Coll Cardiol. 1989; 13(3):617–23.Google Scholar
Grimm, R A, et al. Impact of electrical cardioversion for atrial fibrillation on left atrial appendage function and spontaneous echo contrast: Characterization by simultaneous transesophageal echocardiography. J Am Coll Cardiol. 1993; 22(5):1359–66.Google Scholar
Black, I W, et al. Exclusion of atrial thrombus by transesophageal echocardiography does not preclude embolism after cardioversion of atrial fibrillation. A multicenter study. Circulation. 1994; 89(6):2509–13.Google Scholar
Black, I W, et al. Evaluation of transesophageal echocardiography before cardioversion of atrial fibrillation and flutter in nonanticoagulated patients. Am Heart J. 1993; 126(2):375–81.Google Scholar
Missault, L, et al. Embolic stroke after unanticoagulated cardioversion despite prior exclusion of atrial thrombi by transoesophageal echocardiography. Eur Heart J. 1994; 15(9):1279–80.Google ScholarPubMed
Bjerkelund, C J, Orning, O M. The efficacy of anticoagulant therapy in preventing embolism related to D.C. electrical conversion of atrial fibrillation. Am J Cardiol. 1969; 23(2):208–16.Google Scholar
Oram, S, Davies, J P. Further experience of electrical conversion of atrial fibrillation to sinus rhythm: Analysis of 100 patients. Lancet. 1964; 1(7346):1294–8.Google Scholar
Resnekov, L, McDonald, L. Complications in 220 patients with cardiac dysrhythmias treated by phased direct current shock, and indications for electroconversion. Br Heart J. 1967; 29(6):926–36.Google Scholar
McCarthy, C, Varghese, P J, Barritt, D W. Prognosis of atrial arrhythmias treated by electrical counter shock therapy. A three-year follow-up. Br Heart J. 1969; 31(4):496–500.CrossRefGoogle ScholarPubMed
Berger, M, Schweitzer, P. Timing of thromboembolic events after electrical cardioversion of atrial fibrillation or flutter: A retrospective analysis. Am J Cardiol. 1998; 82(12):1545–7.Google Scholar
Gallagher, M M, et al. Embolic complications of direct current cardioversion of atrial arrhythmias: Association with low intensity of anticoagulation at the time of cardioversion. J Am Coll Cardiol. 2002; 40(5):926–33.Google Scholar
Arnold, A Z, et al. Role of prophylactic anticoagulation for direct current cardioversion in patients with atrial fibrillation or atrial flutter. J Am Coll Cardiol. 1992; 19(4):851–5.Google Scholar
Collins, L J, et al. Cardioversion of nonrheumatic atrial fibrillation. Reduced thromboembolic complications with 4 weeks of precardioversion anticoagulation are related to atrial thrombus resolution. Circulation. 1995; 92(2):160–3.Google Scholar
Israel, C W, et al. Long-term risk of recurrent atrial fibrillation as documented by an implantable monitoring device: implications for optimal patient care. J Am Coll Cardiol. 2004; 43(1):47–52.Google Scholar
Camm, A J, et al. focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J. 2012; 33(21):2719–47.Google Scholar
Camm, A J, et al. Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010; 31(19):2369–429.Google Scholar
www.uptodate.com/contents/warfarin-drug-information?source=see_link. [Accessed September 27, 2015].Google Scholar
Connolly, S J, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009; 361(12):1139–51.CrossRefGoogle ScholarPubMed
www.uptodate.com/contents/warfarin-drug-information?source=see_link. [Accessed September 27, 2015].Google Scholar
Nagarakanti, R, et al. Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion. Circulation. 2011; 123(2):131–6.Google Scholar
www.uptodate.com/contents/warfarin-drug-information?source=see_link. [Accessed on September 27, 2015].Google Scholar
www.uptodate.com/contents/warfarin-drug-information?source=see_link. [Accessed September 27, 2015].Google Scholar
Granger, C B, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011; 365:981–92.Google Scholar
Flaker, G, et al. Efficacy and safety of apixaban in patients after cardioversion for atrial fibrillation: Insights from the ARISTOTLE trial (apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation). Journal of the American College of Cardiology. 2014; 63:1082–7.Google Scholar
Patel, M R, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011; 365:883–91.Google Scholar
Cappato, R, et al. Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation. European Heart Journal. 2014; 35:3346–55.Google Scholar
www.uptodate.com/contents/warfarin-drug-information?source=see_link. [Accessed September 27, 2015].Google Scholar
Weigner, M J, et al. Risk for clinical thromboembolism associated with conversion to sinus rhythm in patients with atrial fibrillation lasting less than 48 hours. Ann Intern Med. 1997; 126:615–20.Google Scholar
Stoddard, M F, et al. Transesophageal echocardiographic guidance of cardioversion in patients with atrial fibrillation. Am Heart J. 1995; 129(6):1204–15.Google Scholar
Stoddard, M F, et al. Left atrial appendage thrombus is not uncommon in patients with acute atrial fibrillation and a recent embolic event: A transesophageal echocardiographic study. J Am Coll Cardiol. 1995; 25(2):452–9.Google Scholar
Klein, A L, et al. Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation. N Engl J Med. 2001; 344(19):1411–20.Google Scholar
Weigner, M J, et al. Early cardioversion of atrial fibrillation facilitated by transesophageal echocardiography: Short-term safety and impact on maintenance of sinus rhythm at 1 year. Am J Med. 2001; 110(9):694–702.Google Scholar
Camm, A J, et al. Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace. 2010; 12(10):1360–420.Google Scholar
www.uptodate.com/contents/warfarin-drug-information?source=see_link. [Accessed September 27, 2015].Google Scholar
References
Tisdale, J E, Miller, D A. American Society of Health-System Pharmacists. Drug-induced Diseases: Prevention, Detection, and Management. Bethesda, MD: American Society of Health-System Pharmacists; 2005.Google Scholar
Flaherty, M L. Anticoagulant-associated intracerebral hemorrhage. Seminars in Neurology. 2010; 30:565–72.Google Scholar
Cantu, C, Arauz, A, Murillo-Bonilla, L M, Lopez, M, Barinagarrementeria, F. Stroke associated with sympathomimetics contained in over-the-counter cough and cold drugs. Stroke. 2003; 34:1667–72.Google Scholar
Plu-Bureau, G, Hugon-Rodin, J, Maitrot-Mantelet, L, Canonico, M. Hormonal contraceptives and arterial disease: An epidemiological update. Best Practice & Research. Clinical Endocrinology & Metabolism. 2013; 27:35–45.Google Scholar
Plu-Bureau, G, Maitrot-Mantelet, L, Hugon-Rodin, J, Canonico, M. Hormonal contraceptives and venous thromboembolism: An epidemiological update. Best Practice & Research. Clinical Endocrinology & Metabolism. 2013; 27:25–34.Google Scholar
Godsland, I F, Winkler, U, Lidegaard, O, Crook, D. Occlusive vascular diseases in oral contraceptive users. Epidemiology, pathology and mechanisms. Drugs. 2000; 60:721–869.Google Scholar
Meade, T W, Greenberg, G, Thompson, S G. Progestogens and cardiovascular reactions associated with oral contraceptives and a comparison of the safety of 50- and 30-microgram oestrogen preparations. British Medical Journal. 1980; 280:1157–61.Google Scholar
Lidegaard, O. Oral contraceptives, pregnancy and the risk of cerebral thromboembolism: The influence of diabetes, hypertension, migraine and previous thrombotic disease. British Journal of Obstetrics and Gynaecology. 1995; 102:153–9.Google Scholar
Lidegaard, O, Kreiner, S. Contraceptives and cerebral thrombosis: A five-year national case-control study. Contraception. 2002; 65:197–205.Google Scholar
Chan, W S, Ray, J, Wai, E K, et al. Risk of stroke in women exposed to low-dose oral contraceptives: A critical evaluation of the evidence. Archives of Internal Medicine. 2004; 164:741–7.Google Scholar
Schurks, M, Rist, P M, Bigal, M E, et al. Migraine and cardiovascular disease: Systematic review and meta-analysis. British Medical Journal. 2009; 339:b3914.Google Scholar
Saposnik, G, Barinagarrementeria, F, Brown, R D Jr., et al. Diagnosis and management of cerebral venous thrombosis: A statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2011; 42:1158–92.Google Scholar
Saadatnia, M, Naghavi, N, Fatehi, F, Zare, M, Tajmirriahi, M. Oral contraceptive misuse as a risk factor for cerebral venous and sinus thrombosis. Journal of Research in Medical Sciences. 2012; 17:344–7.Google Scholar
Ashjazadeh, N, Borhani Haghighi, A, Poursadeghfard, M, Azin, H. Cerebral venous-sinus thrombosis: A case series analysis. Iranian Journal of Medical Sciences. 2011; 36:178–82.Google ScholarPubMed
Martinelli, I, Sacchi, E, Landi, G, et al. High risk of cerebral-vein thrombosis in carriers of a prothrombin-gene mutation and in users of oral contraceptives. New England Journal of Medicine. 1998; 338:1793–7.Google Scholar
de Bruijn, S F, Stam, J, Koopman, M M, Vandenbroucke, J P. The Cerebral Venous Sinus Thrombosis Study Group. Case-control study of risk of cerebral sinus thrombosis in oral contraceptive users and in [correction of who are] carriers of hereditary prothrombotic conditions. British Medical Journal. 1998; 316:589–92.Google Scholar
Dentali, F, Crowther, M, Ageno, W. Thrombophilic abnormalities, oral contraceptives, and risk of cerebral vein thrombosis: A meta-analysis. Blood. 2006; 107:2766–73.Google Scholar
Dunne, C, Malyuk, D, Firoz, T. Cerebral venous sinus thrombosis in a woman using the etonogestrel-ethinyl estradiol vaginal contraceptive ring: A case report. Journal of Obstetrics and Gynaecology Canada. 2010; 32:270–3.Google Scholar
Shetty, K D, Vogt, W B, Bhattacharya, J. Hormone replacement therapy and cardiovascular health in the United States. Medical Care. 2009; 47:600–6.Google Scholar
Rossouw, J E, Anderson, G L, Prentice, R L, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the women’s health initiative randomized controlled trial. Journal of the American Medical Association. 2002; 288:321–33.Google Scholar
Wassertheil-Smoller, S, Hendrix, S L, Limacher, M, et al. Effect of estrogen plus progestin on stroke in postmenopausal women: The women’s health initiative: A randomized trial. Journal of the American Medical Association. 2003; 289:2673–84.Google Scholar
Ruige, J B, Mahmoud, A M, De Bacquer, D, Kaufman, J M. Endogenous testosterone and cardiovascular disease in healthy men: A meta-analysis. Heart. 2011; 97:870–5.Google Scholar
Yeap, B B, Hyde, Z, Almeida, O P, et al. Lower testosterone levels predict incident stroke and transient ischemic attack in older men. Journal of Clinical Endocrinology and Metabolism. 2009; 94:2353–9.Google Scholar
Ferenchick, G, Schwartz, D, Ball, M, Schwartz, K. Androgenic-anabolic steroid abuse and platelet aggregation: A pilot study in weight lifters. American Journal of the Medical Sciences. 1992; 303:78–82.Google Scholar
Stergiopoulos, K, Brennan, J J, Mathews, R, Setaro, J F, Kort, S. Anabolic steroids, acute myocardial infarction and polycythemia: A case report and review of the literature. Vascular Health and Risk Management. 2008; 4:1475–80.Google Scholar
Warkentin, T E, Greinacher, A, Koster, A, Lincoff, A M. Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest. 2008; 133:340S–380S.Google Scholar
Linkins, L A, Dans, A L, Moores, L K, et al. Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012; 141:e495S–530S.Google Scholar
Visentin, G P, Ford, S E, Scott, J P, Aster, R H. Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells. Journal of Clinical Investigation. 1994; 93:81–8.CrossRefGoogle ScholarPubMed
Newman, P M, Chong, B H. Heparin-induced thrombocytopenia: New evidence for the dynamic binding of purified anti-pf4-heparin antibodies to platelets and the resultant platelet activation. Blood. 2000; 96:182–7.Google Scholar
Giossi, A, Del Zotto, E, Volonghi, I, et al. Thromboembolic complications of heparin-induced thrombocytopenia. Blood Coagulation & Fibrinolysis. 2012; 23:559–62.Google Scholar
LaMonte, M P, Brown, P M, Hursting, M J. Stroke in patients with heparin-induced thrombocytopenia and the effect of argatroban therapy. Critical Care Medicine. 2004; 32:976–80.Google Scholar
Li, S H, Chen, W H, Tang, Y, et al. Incidence of ischemic stroke post-chemotherapy: A retrospective review of 10,963 patients. Clinical Neurology and Neurosurgery. 2006; 108:150–6.Google Scholar
Czaykowski, P M, Moore, M J, Tannock, I F. High risk of vascular events in patients with urothelial transitional cell carcinoma treated with cisplatin based chemotherapy. Journal of Urology. 1998; 160:2021–4.Google Scholar
Wall, J G, Weiss, R B, Norton, L, et al. Arterial thrombosis associated with adjuvant chemotherapy for breast carcinoma: A cancer and leukemia group B study. American Journal of Medicine. 1989; 87:501–4.Google Scholar
Bachaud, J M, David, J M, Shubinski, R E, et al. Predictive factors of a complete response to and adverse effects of a cddp-5fu combination as primary therapy for head and neck squamous carcinomas. Journal of Laryngology and Otology. 1993; 107:924–30.Google Scholar
Skali, H, Parving, H H, Parfrey, P S, et al. Stroke in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia treated with darbepoetin alfa: The trial to reduce cardiovascular events with aranesp therapy (treat) experience. Circulation. 2011; 124:2903–8.Google Scholar
Pfeffer, M A, Burdmann, E A, Chen, C Y, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. New England Journal of Medicine. 2009; 361:2019–32.Google Scholar
FDA Drug Safety Communication. Erythropoiesis-stimulating agents (ESAS): Procrit, epogen and aranesp. 2010.Google Scholar
FDA Drug Safety Communication. Modified dosing recommendations to improve the safe use of erythropoiesis-stimulating agents (ESAS) in chronic kidney disease. 2011.Google Scholar
Ehrenreich, H, Weissenborn, K, Prange, H, et al. Recombinant human erythropoietin in the treatment of acute ischemic stroke. Stroke. 2009; 40:e647–656.Google Scholar
Fergusson, D A, Hebert, P C, Mazer, C D, et al. A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. New England Journal of Medicine. 2008; 358:2319–31.Google Scholar
Mangano, D T, Tudor, I C, Dietzel, C. The risk associated with aprotinin in cardiac surgery. New England Journal of Medicine. 2006; 354:353–65.Google Scholar
Roberts, I, Perel, P, Prieto-Merino, D, et al. Effect of tranexamic acid on mortality in patients with traumatic bleeding: Prespecified analysis of data from randomised controlled trial. British Medical Journal. 2012; 345:e5839.Google Scholar
Roos, Y B, Rinkel, G J, Vermeulen, M, Algra, A, van Gijn, J. Antifibrinolytic therapy for aneurysmal subarachnoid haemorrhage. Cochrane Database of Systematic Reviews. 2003: CD001245.Google Scholar
Idbaih, A, Crassard, I, Vahedi, K, Guichard, J P, Woimant, F. Thrombotic cocktail in stroke. Neurology. 2005; 64:334.Google Scholar
Brown, J E, Olujohungbe, A, Chang, J, et al. All-trans retinoic acid (ATRA) and tranexamic acid: A potentially fatal combination in acute promyelocytic leukaemia. British Journal of Haematology. 2000; 110:1010–12.CrossRefGoogle ScholarPubMed
Caress, J B, Cartwright, M S, Donofrio, P D, Peacock, J E Jr. The clinical features of 16 cases of stroke associated with administration of IVIG. Neurology. 2003; 60:1822–4.Google Scholar
Katz, U, Shoenfeld, Y. Review: Intravenous immunoglobulin therapy and thromboembolic complications. Lupus. 2005; 14:802–8.Google Scholar
Orbach, H, Katz, U, Sherer, Y, Shoenfeld, Y. Intravenous immunoglobulin: Adverse effects and safe administration. Clinical Reviews in Allergy & Immunology. 2005; 29:173–84.Google Scholar
Caress, J B, Hobson-Webb, L, Passmore, L V, Finkbiner, A P, Cartwright, M S. Case-control study of thromboembolic events associated with IV immunoglobulin. Journal of Neurology. 2009; 256:339–42.Google Scholar
Haag, M D, Bos, M J, Hofman, A, et al. Cyclooxygenase selectivity of nonsteroidal anti-inflammatory drugs and risk of stroke. Archives of Internal Medicine. 2008; 168:1219–24.Google Scholar
Roumie, C L, Mitchel, E F Jr., Kaltenbach, L, et al. Nonaspirin NSAIDS, cyclooxygenase 2 inhibitors, and the risk for stroke. Stroke. 2008; 39:2037–45.Google Scholar
Andersohn, F, Schade, R, Suissa, S, Garbe, E. Cyclooxygenase-2 selective nonsteroidal anti-inflammatory drugs and the risk of ischemic stroke: A nested case-control study. Stroke. 2006; 37:1725–30.Google Scholar
Fosbol, E L, Olsen, A M, Olesen, J B, et al. Use of nonsteroidal anti-inflammatory drugs among healthy people and specific cerebrovascular safety. International Journal of Stroke. 2012; 9:943–5.Google Scholar
Chang, C H, Shau, W Y, Kuo, C W, Chen, S T, Lai, M S. Increased risk of stroke associated with nonsteroidal anti-inflammatory drugs: A nationwide case-crossover study. Stroke. 2010; 41:1884–90.Google Scholar
Bennett, J S, Daugherty, A, Herrington, D, et al. The use of nonsteroidal anti-inflammatory drugs (NSAIDS): A science advisory from the American Heart Association. Circulation. 2005; 111:1713–16.Google Scholar
Antman, E M, Bennett, J S, Daugherty, A, et al. Use of nonsteroidal antiinflammatory drugs: An update for clinicians: A scientific statement from the American Heart Association. Circulation. 2007; 115:1634–42.Google Scholar
Sklar, P, Masur, H. HIV infection and cardiovascular disease: Is there really a link? New England Journal of Medicine. 2003; 349:2065–7.Google Scholar
Engstrom, J W, Lowenstein, D H, Bredesen, D E. Cerebral infarctions and transient neurologic deficits associated with acquired immunodeficiency syndrome. American Journal of Medicine. 1989; 86:528–32.Google Scholar
Qureshi, A I, Janssen, R S, Karon, J M, et al. Human immunodeficiency virus infection and stroke in young patients. Archives of Neurology. 1997; 54:1150–3.Google Scholar
Mochan, A, Modi, M, Modi, G. Protein S deficiency in HIV associated ischaemic stroke: An epiphenomenon of HIV infection. Journal of Neurology, Neurosurgery, and Psychiatry. 2005; 76:1455–6.Google Scholar
Qureshi, A I. HIV infection and stroke: If not protein S deficiency then what explains the relationship? Journal of Neurology, Neurosurgery, and Psychiatry. 2005; 76:1331.Google Scholar
Vaughn, G, Detels, R. Protease inhibitors and cardiovascular disease: Analysis of the Los Angeles County Adult Spectrum of Disease cohort. AIDS Care. 2007; 19:492–9.Google Scholar
Monsuez, J J, Goujon, C, Wyplosz, B, et al. Cerebrovascular diseases in HIV-infected patients. Current HIV Research. 2009; 7:475–80.Google Scholar
Corral, I, Quereda, C, Moreno, A, et al. Cerebrovascular ischemic events in HIV-1-infected patients receiving highly active antiretroviral therapy: Incidence and risk factors. Cerebrovascular Diseases. 2009; 27:559–63.Google Scholar
Ortiz, G, Koch, S, Romano, J G, Forteza, A M, Rabinstein, A A. Mechanisms of ischemic stroke in HIV-infected patients. Neurology. 2007; 68:1257–61.Google Scholar
Mangili, A, Gerrior, J, Tang, A M, et al. Risk of cardiovascular disease in a cohort of HIV-infected adults: A study using carotid intima-media thickness and coronary artery calcium score. Clinical Infectious Diseases. 2006; 43:1482–9.Google Scholar
Sen, S, Rabinstein, A A, Elkind, M S, Powers, W J. Recent developments regarding human immunodeficiency virus infection and stroke. Cerebrovascular Diseases. 2012; 33:209–18.Google Scholar
Dobbs, M R, Berger, J R. Stroke in HIV infection and AIDS. Expert Review of Cardiovascular Therapy. 2009; 7:1263–71.Google Scholar
Chen, S P, Fuh, J L, Wang, S J. Reversible cerebral vasoconstriction syndrome: Current and future perspectives. Expert Review of Neurotherapeutics. 2011; 11:1265–76.Google Scholar
Salvarani, C, Brown, R D Jr., Hunder, G G. Adult primary central nervous system vasculitis. Lancet. 2012; 380:767–77.Google Scholar
Calabrese, L H, Duna, G F. Drug-induced vasculitis. Current Opinion in Rheumatology. 1996; 8:34–40.Google Scholar
Citron, B P, Halpern, M, McCarron, M, et al. Necrotizing angiitis associated with drug abuse. New England Journal of Medicine. 1970; 283:1003–11.Google Scholar
Lim, D, Rademaker, M, Asztely, F, Ratnaweera, M, Coltman, G. Cerebral vasculitis and multi-focal neurological deficits due to allopurinol-induced hypersensitivity syndrome. Australasian Journal of Dermatology. 2013.Google Scholar
Rothwell, P M, Grant, R. Cerebral vasculitis following allopurinol treatment. Postgraduate Medical Journal. 1996; 72:119–20.Google Scholar
Flaherty, M L, Kissela, B, Woo, D, et al. The increasing incidence of anticoagulant-associated intracerebral hemorrhage. Neurology. 2007; 68:116–21.Google Scholar
Whitlock, R P, Sun, J C, Fremes, S E, Rubens, F D, Teoh, K H. Antithrombotic and thrombolytic therapy for valvular disease: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012; 141:e576S–600S.Google Scholar
You, J J, Singer, D E, Howard, P A, et al. Antithrombotic therapy for atrial fibrillation: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012; 141:e531S–575S.Google Scholar
Ageno, W, Gallus, A S, Wittkowsky, A, et al. Oral anticoagulant therapy: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012; 141:e44S–88S.Google Scholar
Hylek, E M, Skates, S J, Sheehan, M A, Singer, D E. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. New England Journal of Medicine. 1996; 335:540–6.Google Scholar
Hart, R G, Boop, B S, Anderson, D C. Oral anticoagulants and intracranial hemorrhage. Facts and hypotheses. Stroke. 1995; 26:1471–7.Google Scholar
Fang, M C, Go, A S, Chang, Y, et al. Death and disability from warfarin-associated intracranial and extracranial hemorrhages. American Journal of Medicine. 2007; 120:700–5.Google Scholar
Quinones-Hinojosa, A, Gulati, M, Singh, V, Lawton, M T. Spontaneous intracerebral hemorrhage due to coagulation disorders. Neurosurgical Focus. 2003; 15:E3.Google Scholar
Hampton, K K, Preston, F E. ABC of clinical haematology. Bleeding disorders, thrombosis, and anticoagulation. British Medical Journal. 1997; 314:1026–9.Google Scholar
Vernooij, M W, Haag, M D, van der Lugt, A, et al. Use of antithrombotic drugs and the presence of cerebral microbleeds: The Rotterdam scan study. Archives of Neurology. 2009; 66:714–20.Google Scholar
Thompson, B B, Bejot, Y, Caso, V, et al. Prior antiplatelet therapy and outcome following intracerebral hemorrhage: A systematic review. Neurology. 2010; 75:1333–42.Google Scholar
Naidech, A M, Bendok, B R, Garg, R K, et al. Reduced platelet activity is associated with more intraventricular hemorrhage. Neurosurgery. 2009; 65:684–8.Google Scholar
He, J, Whelton, P K, Vu, B, Klag, M J. Aspirin and risk of hemorrhagic stroke: A meta-analysis of randomized controlled trials. Journal of the American Medical Association. 1998; 280:1930–5.Google Scholar
Foerch, C, Sitzer, M, Steinmetz, H, Neumann-Haefelin, T. Pretreatment with antiplatelet agents is not independently associated with unfavorable outcome in intracerebral hemorrhage. Stroke. 2006; 37:2165–7.Google Scholar
Toyoda, K, Okada, Y, Minematsu, K, et al. Antiplatelet therapy contributes to acute deterioration of intracerebral hemorrhage. Neurology. 2005; 65:1000–4.Google Scholar
Toyoda, K, Yasaka, M, Nagata, K, et al. Antithrombotic therapy influences location, enlargement, and mortality from intracerebral hemorrhage. The bleeding with antithrombotic therapy (BAT) retrospective study. Cerebrovascular Diseases. 2009; 27:151–9.Google Scholar
Saloheimo, P, Ahonen, M, Juvela, S, et al. Regular aspirin-use preceding the onset of primary intracerebral hemorrhage is an independent predictor for death. Stroke. 2006; 37:129–33.Google Scholar
Creutzfeldt, C J, Weinstein, J R, Longstreth, W T Jr., et al. Prior antiplatelet therapy, platelet infusion therapy, and outcome after intracerebral hemorrhage. Journal of Stroke & Cerebrovascular Diseases. 2009; 18:221–8.Google Scholar
Caso, V, Paciaroni, M, Venti, M, et al. Effect of on-admission antiplatelet treatment on patients with cerebral hemorrhage. Cerebrovascular Diseases. 2007; 24:215–18.Google Scholar
Roquer, J, Rodriguez Campello, A, Gomis, M, et al. Previous antiplatelet therapy is an independent predictor of 30-day mortality after spontaneous supratentorial intracerebral hemorrhage. Journal of Neurology. 2005; 252:412–16.Google Scholar
Lacut, K, Le Gal, G, Seizeur, R, et al. Antiplatelet drug use preceding the onset of intracerebral hemorrhage is associated with increased mortality. Fundamental & Clinical Pharmacology. 2007; 21:327–33.Google Scholar
Hanger, H C, Fletcher, V J, Wilkinson, T J, et al. Effect of aspirin and warfarin on early survival after intracerebral haemorrhage. Journal of Neurology. 2008; 255:347–52.Google Scholar
Sansing, L H, Messe, S R, Cucchiara, B L, et al. Prior antiplatelet use does not affect hemorrhage growth or outcome after ICH. Neurology. 2009; 72:1397–402.Google Scholar
Moussouttas, M, Malhotra, R, Fernandez, L, et al. Role of antiplatelet agents in hematoma expansion during the acute period of intracerebral hemorrhage. Neurocritical Care. 2010; 12:24–9.Google Scholar
Stead, L G, Jain, A, Bellolio, M F, et al. Effect of anticoagulant and antiplatelet therapy in patients with spontaneous intra-cerebral hemorrhage: Does medication use predict worse outcome? Clinical Neurology & Neurosurgery. 2010; 112:275–81.Google Scholar
Ishibashi, A, Yokokura, Y, Adachi, H. Is antiplatelet therapy for the prevention of ischemic stroke associated with the prognosis of intracerebral hemorrhage? Kurume Medical Journal. 2008; 55:71–5.Google Scholar
Nicolini, A, Ghirarduzzi, A, Iorio, A, et al. Intracranial bleeding: Epidemiology and relationships with antithrombotic treatment in 241 cerebral hemorrhages in Reggio Emilia. Haematologica. 2002; 87:948–56.Google Scholar
Baldi, G, Altomonte, F, Altomonte, M, et al. Intracranial haemorrhage in patients on antithrombotics: Clinical presentation and determinants of outcome in a prospective multicentric study in Italian emergency departments. Cerebrovascular Diseases. 2006; 22:286–93.Google Scholar
Lovelock, C E, Cordonnier, C, Naka, H, et al. Antithrombotic drug use, cerebral microbleeds, and intracerebral hemorrhage: A systematic review of published and unpublished studies. Stroke. 2010; 41:1222–8.Google Scholar
Naidech, A M, Bernstein, R A, Levasseur, K, et al. Platelet activity and outcome after intracerebral hemorrhage. Annals of Neurology. 2009; 65:352–6.Google Scholar
Naidech, A M, Jovanovic, B, Liebling, S, et al. Reduced platelet activity is associated with early clot growth and worse 3-month outcome after intracerebral hemorrhage. Stroke. 2009; 40:2398–401.Google Scholar
de Gans, K, de Haan, R J, Majoie, C B, et al. PATCH: Platelet Transfusion in Cerebral Haemorrhage: Study protocol for a multicentre, randomised, controlled trial. BMC Neurology. 2010; 10:19.Google Scholar
Memon, M A, Blankenship, J C, Wood, G C, Frey, C M, Menapace, F J. Incidence of intracranial hemorrhage complicating treatment with glycoprotein IIb/IIIa receptor inhibitors: A pooled analysis of major clinical trials. American Journal of Medicine. 2000; 109:213–17.Google Scholar
Qureshi, A I, Suri, M F, Ali, Z, et al. Carotid angioplasty and stent placement: A prospective analysis of perioperative complications and impact of intravenously administered abciximab. Neurosurgery. 2002; 50:466–73.Google Scholar
Qureshi, A I, Saad, M, Zaidat, O O, et al. Intracerebral hemorrhages associated with neurointerventional procedures using a combination of antithrombotic agents including abciximab. Stroke. 2002; 33:1916–19.Google Scholar
Adams, H P Jr., Effron, M B, Torner, J, et al. Emergency administration of abciximab for treatment of patients with acute ischemic stroke: Results of an international phase III trial: Abciximab in emergency treatment of stroke trial (ABESTT-II). Stroke. 2008; 39:87–99.Google Scholar
Adams, H P Jr., Leira, E C, Torner, J C, et al. Treating patients with “wake-up” stroke: The experience of the ABESTT-II trial. Stroke. 2008; 39:3277–82.Google Scholar
Hirsh, J, Guyatt, G, Albers, G W, Harrington, R, Schunemann, H J, American College of Chest Physicians. Antithrombotic and thrombolytic therapy: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest. 2008; 133:110S–112S.Google Scholar
The National Institute of Neurological Disorders and Stroke RT-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. New England Journal of Medicine. 1995; 333:1581–7.Google Scholar
Strbian, D, Sairanen, T, Meretoja, A, et al. Patient outcomes from symptomatic intracerebral hemorrhage after stroke thrombolysis. Neurology. 2011; 77:341–8.Google Scholar
Herrmann, N, Lanctot, K L. Do atypical antipsychotics cause stroke? CNS Drugs. 2005; 19:91–103.Google Scholar
Sacchetti, E, Turrina, C, Valsecchi, P. Cerebrovascular accidents in elderly people treated with antipsychotic drugs: A systematic review. Drug Safety. 2010; 33:273–88.Google Scholar
Christensen, S, Mehnert, F, Chapurlat, R D, Baron, J A, Sorensen, H T. Oral bisphosphonates and risk of ischemic stroke: A case-control study. Osteoporosis International. 2011; 22:1773–9.Google Scholar
Wilkinson, G S, Baillargeon, J, Kuo, Y F, Freeman, J L, Goodwin, J S. Atrial fibrillation and stroke associated with intravenous bisphosphonate therapy in older patients with cancer. Journal of Clinical Oncology. 2010; 28:4898–905.Google Scholar
Gallagher, A M, Smeeth, L, Seabroke, S, Leufkens, H G, van Staa, T P. Risk of death and cardiovascular outcomes with thiazolidinediones: A study with the general practice research database and secondary care data. PloS One. 2011; 6:e28157.Google Scholar
Panicker, G K, Karnad, D R, Salvi, V, Kothari, S. Cardiovascular risk of oral antidiabetic drugs: Current evidence and regulatory requirements for new drugs. J Assoc Physicians India. 2012; 60:56–61.Google Scholar
Morgenstern, L B, Hemphill, J C 3rd, Anderson, C, et al. Guidelines for the management of spontaneous intracerebral hemorrhage: A guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2010; 41:2108–29.Google Scholar
Jauch, E C, Saver, J L, Adams, H P Jr. et al. Guidelines for the early management of patients with acute ischemic stroke: A guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2013; 44:870–947.Google Scholar
Ducros, A, Bousser, M G. Reversible cerebral vasoconstriction syndrome. Practical Neurology. 2009; 9:256–67.Google Scholar
Mittal, M K, Rabinstein, A A. Anticoagulation-related intracranial hemorrhages. Current Atherosclerosis Reports. 2012; 14:351–9.Google Scholar
Hirsh, J, Anand, S S, Halperin, J L, Fuster, V. Mechanism of action and pharmacology of unfractionated heparin. Arteriosclerosis, Thrombosis, and Vascular Biology. 2001; 21:1094–6.Google Scholar
Choay, J, Petitou, M, Lormeau, JC, et al. Structure-activity relationship in heparin: A synthetic pentasaccharide with high affinity for antithrombin III and eliciting high anti-factor Xa activity. Biochemical and Biophysical Research Communications. 1983; 116:492–9.Google Scholar
Crowther, M A, Warkentin, T E. Bleeding risk and the management of bleeding complications in patients undergoing anticoagulant therapy: Focus on new anticoagulant agents. Blood. 2008; 111:4871–9.Google Scholar
Watanabe, M, Siddiqui, F M, Qureshi, A I. Incidence and management of ischemic stroke and intracerebral hemorrhage in patients on dabigatran etexilate treatment. Neurocritical Care. 2012; 16:203–9.Google Scholar
Konkle, B A. Acquired disorders of platelet function. ASH Education Program Book. 2011; 391–6.Google Scholar
Kenney, B, Stack, G. Drug-induced thrombocytopenia. Archives of Pathology and Laboratory Medicine. 2009; 133:309–14.Google Scholar
Steiner, T, Poli, S, Griebe, M, et al. Fresh frozen plasma versus prothrombin complex concentrate in patients with intracranial haemorrhage (INCH): a randomized trial. Lancet. 2016; 15:566–73.Google Scholar
Pollack, C V, Reilly, P A, Eikelboom, J, et al. Idarucizamab for dibigatran reversal. New England Journal of Medicine. 2015; 373:511–20.Google Scholar